DRMA (dermatarx.com) Market Value to Book Value Ratio

Dermata Therapeutics (DRMA) is implementing advanced component delivery methods into deep skin layers to combat inflammation. On GURU.Markets, the current market-to-book multiple trend demonstrates the market valuation of the company developing treatments for rosacea and acne. Since the business is in the clinical stage and relies on equity offerings, the value of 0.87 reflects the balance between the market value and the book value of assets.

Dermata Therapeutics (DRMA) focuses on developing dermatological drugs and currently has no operating revenue. The mvsbcap_co metric compares the company's market value to its net assets, revealing the size of the premium attributed to future success. By analyzing the historical market cap to book value ratio on GURU.Markets, an investor can see how the valuation depends on the stages of clinical trials. An increase in this indicator signals market optimism regarding intellectual property, while a high ratio confirms the speculative nature of the cost of capital.